Pulmonary Embolism-Pipeline Review, H1 2016

Pulmonary Embolism-Pipeline Review, H1 2016


  • Products Id :- GMDHC7800IDB
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Pulmonary Embolism-Pipeline Review, H1 2016', provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism

The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects

The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pulmonary Embolism Overview 6

Therapeutics Development 7

Pipeline Products for Pulmonary Embolism-Overview 7

Pipeline Products for Pulmonary Embolism-Comparative Analysis 8

Pulmonary Embolism-Therapeutics under Development by Companies 9

Pulmonary Embolism-Therapeutics under Investigation by Universities/Institutes 10

Pulmonary Embolism-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Pulmonary Embolism-Products under Development by Companies 14

Pulmonary Embolism-Products under Investigation by Universities/Institutes 15

Pulmonary Embolism-Companies Involved in Therapeutics Development 16

Accu-Break Pharmaceuticals, Inc. 16

Bristol-Myers Squibb Company 17

F. Hoffmann-La Roche Ltd. 18

Pulmonary Embolism-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 25

Drug Profiles 26

apixaban-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

TMS-007-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

TRX-1-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

warfarin potassium-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Pulmonary Embolism-Recent Pipeline Updates 32

Pulmonary Embolism-Dormant Projects 40

Pulmonary Embolism-Discontinued Products 41

Pulmonary Embolism-Product Development Milestones 42

Featured News & Press Releases 42

Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 42

Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 43

Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 44

Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 44

Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 45

Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 46

Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 47

Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 48

Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 49

May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Figures

Number of Products under Development for Pulmonary Embolism, H1 2016 7

Number of Products under Development for Pulmonary Embolism-Comparative Analysis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy Products, H1 2016 19

Number of Products by Targets, H1 2016 20

Number of Products by Stage and Targets, H1 2016 20

Number of Products by Mechanism of Actions, H1 2016 22

Number of Products by Stage and Mechanism of Actions, H1 2016 22

Number of Products by Stage and Routes of Administration, H1 2016 24

Number of Products by Stage and Molecule Types, H1 2016 25

List of Tables

Number of Products under Development for Pulmonary Embolism, H1 2016 7

Number of Products under Development for Pulmonary Embolism-Comparative Analysis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Number of Products under Investigation by Universities/Institutes, H1 2016 10

Comparative Analysis by Late Stage Development, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Pulmonary Embolism-Pipeline by Accu-Break Pharmaceuticals, Inc., H1 2016 16

Pulmonary Embolism-Pipeline by Bristol-Myers Squibb Company, H1 2016 17

Pulmonary Embolism-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 18

Assessment by Monotherapy Products, H1 2016 19

Number of Products by Stage and Target, H1 2016 21

Number of Products by Stage and Mechanism of Action, H1 2016 23

Number of Products by Stage and Route of Administration, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 25

Pulmonary Embolism Therapeutics-Recent Pipeline Updates, H1 2016 32

Pulmonary Embolism-Dormant Projects, H1 2016 40

Pulmonary Embolism-Discontinued Products, H1 2016 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Accu-Break Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Pulmonary Embolism Therapeutic Products under Development, Key Players in Pulmonary Embolism Therapeutics, Pulmonary Embolism Pipeline Overview, Pulmonary Embolism Pipeline, Pulmonary Embolism Pipeline Assessment

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com